Lundbeck swaps alcohol dependence royalties for equity, untangles Biotie
This article was originally published in Scrip
Executive Summary
Lundbeck has amended its licensing agreement with Biotie Therapies for the companies' alcohol dependence treatment Selincro (nalmefene) and acquired a 5% stake in its partner.